Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

Nature Medicine

Volumn 2, Issue 8, 1996, Pages 864-870

  Scheuner, D ^a,l   Eckman, C ^a,b   Jensen, M ^c   Song, X ^a   Citron, M ^d   Suzuki, N ^e   Bird, T D ^f,h   Hardy, J ^j   Hutton, M ^j   Kukull, W ^f   Larson, E ^f   Levy Lahad, E ^f,i   Viitanen, M ^c   Peskind, E ^g,i   Poorkaj, P ^f,i   Schellenberg, G ^f,g,i   Tanzi, R ^k   Wasco, W ^k   Lannfelt, L ^c   Selkoe, D ^d   Younkin, S ^b   more..

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

^e TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h Neurology Service   (United States)

ⁱ Education   (United States)

^j UNIVERSITY OF SOUTH FLORIDA   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; FAMILIAL DISEASE; FEMALE; FIBROBLAST CULTURE; GENE MUTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; FEMALE; FIBROBLASTS; HUMANS; MALE; MEMBRANE PROTEINS; MUTATION; PEPTIDE FRAGMENTS; PRESENILIN-1; PRESENILIN-2;

EID: 16044373524     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0896-864     Document Type: Article

References (40)

1. Iwatsubo, T., Mann, D.M., Odaka, A., Suzuki, N. & Ihara, Y. Amyloid beta protein (Aβ) deposition: Aβ42(43) precedes Aβ-40 in Down syndrome. Ann. Neurol. 37, 294-299 (1995).
2. Gravina, S.A. et al. Amyloid beta protein (Aβ) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at Aβ40 or Aβ42(43). J. Biol. Chem. 270, 7013-7016 (1995).
3. Roher, A. et al. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J. Biol. Chem. 268, 3072-3083 (1993).
4. Miller, D.L. et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. 301, 41-52 (1993).
5. Seubert, P. et al. Isolation and quantification of soluble Alzheimer's betapeptide from biological fluids. Nature 359, 325-327 (1992).
6. Shoji, M. et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258, 126-129 (1992).
7. Haass, C. et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359, 322-325 (1992).
8. Busciglio, J. Gabuzda, D.H., Matsudaira, P. & Yankner, B.A. Generation of betaamyloid in the secretory pathway in neuronal and nonneuronal cells. Proc. Natl. Acad. Sci. USA 90, 2092-2096 (1993).
9. Dovey, H.F., Suomesaari-Chrysler, S., Lieberburg, I., Sinha, S. & Kiem, P.S. Cells with a familial Alzheimer's disease mutation produce authentic β-peptide. NeuroReport 4, 1039-1042 (1993).
10. Vigo-Pelfrey, C., Lee, D., Keim, P., Lieberburg, I. & Schenk, D. B. Characterization of β amyloid peptide from human cerebrospinal fluid. J. Neurochem. 61, 19965-19968 (1993).
11. Hilbich, C., Kisters-Woike, B., Reed, J., Masters, C.L. & Beyreuther, K. Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease. J. Mol. Biol. 218, 149-163 (1991).
12. Burdick, D. et al. Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J. Biol. Chem. 267, 546-554 (1992).
13. Jarrett, J.T. & Lansbury, P.T. Jr. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058 (1993).
14. Jarrett, J.T., Berger, E.P. & Lansbury, P.T. Jr. The carboxy terminus of β amyloid protein is critical for the seeding of amyloid formation: Implications for pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697 (1993).
15. Sherrington, R. et al. Cloning of a gene bearing missense mutations in earlyonset familial Alzheimer's disease. Nature 375, 754-760 (1995).
16. Levy-Lahad, E. et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973-977 (1995).
17. Levy-Lahad, E. et al. A familial Alzheimer's disease locus on chromosome 1. Science 269, 970-973 (1995).
18. Rogaev, E. et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775-778 (1995).
19. Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706 (1991).
20. Naruse, S. et al. Missense mutation Val-Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease. Lancet 337, 978 (1991).
21. Yoshioka, K., Miki, T., Katsuya, T., Ogihara, T. & Sakaki, Y. The 717Val-Ile substitution in amyloid precursor protein is associated with familial Alzheimer's disease regardless of ethnic groups. Biocliein. Bioplys. Res. Commun. 178, 1141 (1991).
22. Hardy, J. et al. Molecular classification of Alzheimer's disease. Lancet 337, 1342 (1991).
23. Murrell, J., Farlow, M., Ghetti, B. & Benson, M.D. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 254, 97-99 (1991).
24. Chartier-Harlin, M.-C. et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 353, 844-846 (1991).
25. Mullan, M. et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nature Genet. 1, 345-347 (1992).
26. Citron, M. et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc. Natl. Acad. Sci. USA 91, 11993-11997 (1994).
27. Gai, X.D., Golde, T.E. & Younkin, S.G. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 259, 514-516 (1993).
28. Citron, M. et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 360, 672-674 (1992).
29. Suzuki, N. et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (β APP717) mutants. Science 264, 1336-1340 (1994).
30. Tamaoka, A. et al. APP717 missense mutation affects the ratio of amyloid beta protein species (Aβ1-42/43 and Aβ1-40) in familial Alzheimer's disease brain. J. Biol. Chem. 269, 32721-32724 (1994).
31. Motter, R. et al. Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38, 643-648 (1995).
32. Grubb, A. et al. Abnormal metabolism of gamma-trace alkaline microprotein. The basic defect in hereditary cerebral hemorrhage with amyloidosis. N. Engl. J. Med. 311, 1547-1549 (1984).
33. Ma, J., Yee, A., Brewer, H.B. Jr., Das, S. & Potter, H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372, 92-94 (1994).
34. Wisniewski, T., Castano, E.M., Golabek, A. Vogel, T. & Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145, 1030-1035 (1994).
35. Castaño, E. et al. Fibrillogenesis in Alzheimer's disease of the amyloid beta peptides and apolipoprotein E. Biochem. J. 306, 599-604 (1995).
36. Evans, K.C., Berger, E.P., Cho, C.G., Weisgraber, K.H. & Lansbury, P.T. Jr. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 92, 763-767 (1995).
37. Larson, E.B. et al. University of Washington Alzheimer's Disease Patient Registry (ADPR): 1987-1988. Aging 2, 404-408 (1990).
38. Kukull, W.A. et al. Solvent exposure as a risk factor for Alzheimer's disease: A case-control study. Am. J. Epidemiol. 141, 1059-1071 (1995); (erratum) Am. J. Epidemiol. 142, 450 (1996).
39. Kukull, W.A. et al. Solvent exposure as a risk factor for Alzheimer's disease: A case-control study. Am. J. Epidemiol. 141, 1059-1071 (1995); (erratum) Am. J. Epidemiol. 142, 450 (1996).
40. McKhann, G. et al Clinical diagnosis of Alzheimer's disease: Report of the NINCSDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34, 939-944 (1984).